Search This Blog

Friday, January 24, 2020

Alpine Immune Sciences up on encouraging data on lead candidate

Thinly traded nano cap Alpine Immune Sciences (NASDAQ:ALPN) is up 8% premarket, albeit on only 1,008 shares, on the heels of new preclinical data on lead candidate ALPN-101. The results were presented at the Crohn’s & Colitis Congress in Austin, TX.
In a T cell transfer model of chronic inflammatory bowel disease (IBD), ALPN-101 showed “superior” suppression of proinflammatory cytokines in vitro compared to single CD28 or ICOS pathway inhibitors in peripheral blood mononuclear cells from a colitis patient. It also showed effector memory T cell and cytokine suppression in mouse models of IBD.
ALPN-101 is a dual CD28/ICOS antagonist also in development for graft-versus-host disease.
https://seekingalpha.com/news/3534340-alpine-immune-sciences-up-8-premarket-on-encouraging-data-on-lead-candidate

Sonoma Pharma up 20% premarket on potential sale of U.S. dermatology unit

Thinly traded nano cap Sonoma Pharmaceuticals (NASDAQ:SNOA) has engaged Maxim Group LLC to assist in exploring strategic alternatives for its U.S. Dermatology Division.
Shares up 20% premarket on average volume.
https://seekingalpha.com/news/3534326-sonoma-pharma-up-20-premarket-on-potential-sale-of-u-s-dermatology-unit

Kitov Pharma nabs European patent for NT-219; shares up 26% premark

Thinly traded nano cap Kitov Pharma (NASDAQ:KTOV) is up 26% premarket on increased volume in reaction to its announcement that it has received a Notice of Intention to Grant from the European Patent Office regarding a patent covering the use of NT-219, in combination with EGFR antibodies and inhibitors, to treat cancer.
https://seekingalpha.com/news/3534329-kitov-pharma-nabs-european-patent-for-ntminus-219-shares-up-26-premarket

Bellicum up 9% premarket on BPX-601 data

Bellicum Pharmaceuticals (NASDAQ:BLCM) perks up 9% premarket on light volume on the heels of Phase 1 translational data on lead GoCAR-T candidate BPX-601 in patients with advanced pancreatic cancer. The results were presented at the ASCO GI Cancers Symposium in San Francisco.
Data from cohort 5B showed enhanced survival and persistence up to nine months.
Activation of BPX-601 GoCAR-T cells mediated upregulation of immunomodulatory cytokines and infiltrated metastatic pancreatic tumors.
Changes in tumor microenvironment gene expression were consistent with a productive CAR-T cell immune response observed in patients treated with BPX-601 activated by rimiducid.
Development is ongoing.
https://seekingalpha.com/news/3534305-bellicum-up-9-premarket-on-bpxminus-601-data

Coronavirus in China: Officials rush to build hospital in 10 days


Heavy equipment works at a construction site for a field hospital in Wuhan in central China's Hubei Province.
Heavy equipment works at a construction site for a field hospital in Wuhan in central China’s Hubei Province.

China is rushing to build a 1,000-bed hospital in just 10 days to treat patients at the epicenter of the new coronavirus, which has killed at least 26 people, infected about 830 and prompted lockdowns in at least a dozen cities, according to reports.
The 270,000-square-foot in Wuhan is expected to be up and running by Feb. 3 and will aim “to address the insufficiency of existing medical resources,” city officials said, according to the official Xinhua news agency.
On the eve of the Lunar New Year, transportation was shut down Friday in 12 cities with a total of about 35 million, including Wuhan and its neighbors in central China’s Hubei province.
In 2003, China built a hospital on Beijing’s rural outskirts in barely a week to treat a rapidly rising number of people suffering from SARS, or Severe Acute Respiratory Syndrome, which killed 349 people in mainland China and 299 in Hong Kong.
Xiaotangshan Hospital comprised prefabricated structures and Xinhua reported Friday that Wuhan was building the new facility based on the same model.
The city of over 11 million residents has been centralizing its treatment of the coronavirus by isolating patients in 61 clinics and designated hospitals.
Officials have said the news virus probably originated from wild animals at a seafood market in Wuhan but it has since spread to several countries around Asia and beyond.
Meanwhile, at least eight hospitals in Wuhan issued calls for donations of masks, goggles, gowns and other protective gear, according to online notices online.
Officials at Wuhan University People’s Hospital set up a group chat on the popular WeChat messaging app to coordinate the donations.
The “Fever Control Command Center” of the city of Huanggang also issued a call for donations publicized by the state-run People’s Daily, asking for medical supplies, medicine and disinfection equipment. The notice added that for now, they wouldn’t accept supplies from other countries.
The vast majority of cases were reported in and around Wuhan, but people who visited or had personal connections to infected people were among the scattered cases counted beyond the mainland.
South Korea and Japan both confirmed their second cases Friday and Singapore confirmed its third. Cases also have been detected in Hong Kong, Macao, Taiwan, Thailand and Vietnam.
One case also has turned up in the US. A Washington State man in his 30s has been diagnosed after returning from a solo trip to Wuhan.
https://nypost.com/2020/01/24/coronavirus-in-china-officials-rush-to-build-hospital-in-10-days/

Exelixis up 1% premarket on Cabometyx data in liver cancer

Exelixis (NASDAQ:EXEL) perks up 1% premarket on light volume on the heels of results from an open-label Phase 1/2 clinical trial, CheckMate 040, evaluating the combination of Cabometyx (cabozantinib) and Bristol-Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab), with or without Yervoy (ipilimumab), in patients with advanced hepatocellular carcinoma (HCC). The data are being presented today at the ASCO GI Cancers Symposium in San Francisco.
In treatment-naïve patients receiving cabozantinib and nivolumab (n=17) and those receiving prior treatment with Bayer’s Nexavar (sorafenib) (n=19), the objective response rate (ORR) was 19% and the disease control rate (responders + stable cancer) was 75%. Median progression-free survival (PFS) was 5.4 months while median overall survival (OS) was 21.5 months.
In 35 patients receiving cabozantinib, nivolumab and ipilimumab (12 treatment-naïve), including 23 with prior sorafenib therapy, ORR was 29%, DCR was 83% and median PFS was 6.8 months. Median OS had not been reached at data cutoff.
No new safety signals were observed.
https://seekingalpha.com/news/3534313-exelixis-up-1-premarket-on-cabometyx-data-in-liver-cancer

Analyst action, Jan. 24

AzurRx BioPharma (NASDAQ:AZRX) resumed with Buy rating and $7 (554% upside) price target at Roth Capital Partners.
IVERIC bio (NASDAQ:ISEE) initiated with Outperform rating and $15 (123% upside) price target at Cowen and Company.
Matinas BioPharma Holdings (NYSEMKT:MTNB) initiated with Buy rating and $3 (99% upside) price target at SunTrust. Shares up 5% premarket.
Pacira BioSciences (NASDAQ:PCRX) initiated with Buy rating and $60 (37% upside) price target at SunTrust.
Provention Bio (NASDAQ:PRVB) initiated with Overweight rating and $25 (51% upside) price target at Cantor Fitzgerald. Shares up 3% premarket.
BioMarin Pharmaceutical (NASDAQ:BMRN) upgraded to Outperform with a $113 (32% upside) price target at RBC citing bullish prospects for hemophilia gene therapy valrox.
DaVita (NYSE:DVA) upgraded to Buy with a $97 (20% upside) price target at Goldman Sachs. Shares up 2% premarket.
BioNTech SE (NASDAQ:BNTX) downgraded to Market Perform with a $31 (16% downside risk) price target at SVB Leerink. Shares down 2% premarket.
Epizyme (NASDAQ:EPZM) downgraded to Market Perform with an $18 (33% downside risk) price target at SVB Leerink. Shares down 5% premarket.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) downgraded to Hold at Gabelli.
https://seekingalpha.com/news/3534298-rbc-likes-biomarin-in-premarket-analyst-action